Post-COVID-19 Syndrome: Incidence, Risk Factor, and the Most Common Persisting Symptoms.

Autor:	Alghamdi SA; Infectious Diseases, King Abdulaziz University Hospital, Jeddah, SAU., Alfares MA; Infectious Diseases, King Abdulaziz University Hospital, Jeddah, SAU., Alsulami RA; Infectious Diseases, King Abdulaziz University Hospital, Jeddah, SAU., Alghamdi AF; Infectious Diseases, King Abdulaziz University Hospital, Jeddah, SAU., Almalawi AM; Infectious Diseases, King Abdulaziz University Hospital, Jeddah, SAU., Alghamdi MS; Infectious Diseases, King Abdulaziz University Hospital, Jeddah, SAU., Hazazi HA; Infectious Diseases, King Abdulaziz University Hospital, Jeddah, SAU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Nov 30; Vol. 14 (11), pp. e32058. Date of Electronic Publication: 2022 Nov 30 (Print Publication: 2022).
DOI:	10.7759/cureus.32058
Abstrakt:	Introduction: The pandemic of the coronavirus disease 2019 (COVID-19) has caused a significant burden worldwide. The most common presentation of coronavirus disease is acute, and most patients recover completely. However, now a substantial proportion of patients experience long-term health effects. Post-COVID-19 syndrome (PCS) is defined as "signs and symptoms that develop after an infection consistent with COVID-19 that persist for more than 12 weeks and have not been explained yet by an alternative diagnosis." We faced a lack of studies regarding PCS in the Gulf area. Therefore, this study aimed to assess the incidence, risk factors, and most common persisting symptoms of PCS in confirmed COVID-19 patients who presented to King Abdulaziz University Hospital (KAUH) in Jeddah between June 1, 2020 and December 31, 2020. Methods: This retrospective cohort study was conducted via telephone survey, which took place in June 2022 at KAUH. PCS was defined as the presence of one or more symptoms beyond 12 weeks from the onset of the illness. The inclusion criteria were patients aged 18 or above with laboratory-confirmed SARS-CoV-2 infection through positive RT-PCR in KAUH from June 1, 2020 to December 31, 2020, and both genders were included. The exclusion criteria were inability to provide informed consent, death, currently active COVID-19 infection (PCR +ve), and if they did not complete the interview. Medical records were obtained from patients diagnosed with COVID-19 through positive RT-PCR tests from June 1, 2020 to December 31, 2020. Results: Data of 504 patients were analyzed. The incidence of PCS was 45.0% (95%CI, 40.7% to 49.5%). PCS was associated with female gender (OR = 1.71, 95%CI, 1.13 to 2.59, p = 0.011), having three or more co-morbid conditions (OR = 2.37, 95%CI, 1.19 to 4.75, p = 0.014), receiving steroids (OR = 2.13, 95%CI, 1.16 to 3.98, p = 0.016), also patients who experienced congestion (OR = 1.68, 95%CI, 1.05 to 2.71, p = 0.032) and depression (OR = 1.80, 95%CI, 1.03 to 3.18, p = 0.039) during acute COVID-19 infection. The most commonly reported symptoms beyond 12 weeks included fatigue (19.6%), joint pain (14.1%), and decreased exercise tolerance (12.7%). Conclusion: In conclusion, the main risk factors to develop PCS are being female, having three or more co-morbidities, receiving steroids, or patients presenting with nasal congestion and/or depression. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Alghamdi et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu